About HRPHF
Partners and Links
HRPHF Connection
Online Giving
©  2009 All Rights Reserved  •  Hampton Roads Prostate Health Forum | Hampton, VA
Contact the Forum
Reach out to the Forum in a number of ways: 

Web Address: www.hrprostatehealth.org

Email: (general) info@hrprostatehealth.org 
(donations) donations@hrprostatehealth.org

Mailing Address: P.O. Box 6269, Norfolk, VA 23508

Office Number: (757) 

Fax Number: (757) 

Social Networking: 
HRPHF is a 501(c)(3) organization.
HOMERESEARCHAWARENESSEDUCATIONEARLY DETECTIONNAVIGATORTREATMENTSUPPORT

Awareness 
The Forum plays a key role in alerting and informing the public about the number of men in general and men in high risk groups in particular who die from prostate cancer each year.
Facts about Prostate Cancer page 
Hampton Roads Prostate Health Forum Disputes Government Panel’s Recommendation on Prostate Cancer Screening

“The Hampton Roads Prostate Health Forum (HRPHF) is deeply disappointed that the U.S. Preventive Services Task Force has failed to amend the draft recommendation on prostate cancer it issued in October, 2011,” said Charlie Hill, HRPHF president and co-founder. “This recommendation,” said Hill, “continues to negate the demonstrated benefits of the Prostate Specific Antigen, PSA, test in the diagnosis of prostate cancer. It at once encourages primary care physicians not to prescribe the test and hesitant patients not to request it.” Hill added, “The recommendation is likely to dramatically shorten the lives of men at the highest risk of having prostate cancer.”
The U.S. Preventive Services Task Force's (USPSTF) final recommendation essentially instructs physicians to discourage asymptomatic men from having the PSA test. This comes despite overwhelming opposition from urologists, oncologists, prostate cancer survivors, and their caretakers, most of whom are wives, daughters, sisters, and friends.
“There is strong evidence that PSA testing saves lives,” added Hill, a prostate cancer survivor/warrior. He notes the European Randomized Study for the Screening of Prostate Cancer (ERSPC), the largest study of its kind, published in the March 2012 issue of the New England Journal of Medicine. “This study demonstrated a 21% survival advantage in PSA screenings for all patients. It further stated that, for those with the longest follow-up, over 10 years, the survival rate increased to 38%. This is consistent with the experience in the United States, where death rates from prostate cancer have declined by nearly 40% over the last two decades.”    PAGE 2



Charlie W. Hill
President